OneSource Specialty Pharma Ltd

OneSource Specialty Pharma Ltd

₹ 1,677 0.05%
22 May 9:35 a.m.
About

Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]

Key Points

Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.

  • Market Cap 19,194 Cr.
  • Current Price 1,677
  • High / Low 1,800 / 1,163
  • Stock P/E 235
  • Book Value 514
  • Dividend Yield 0.00 %
  • ROCE 5.39 %
  • ROE 2.60 %
  • Face Value 1.00

Pros

Cons

  • Stock is trading at 3.27 times its book value
  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -3.52%
  • Company has a low return on equity of -18.2% over last 3 years.
  • Debtor days have increased from 86.2 to 105 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
34 56 73 78 334 393 426
72 67 76 73 257 251 243
Operating Profit -39 -10 -3 5 77 142 183
OPM % -114% -19% -4% 7% 23% 36% 43%
-32 -74 3 1 -1 -94 2
Interest 25 26 20 20 45 46 33
Depreciation 18 20 20 19 68 69 68
Profit before tax -114 -130 -40 -33 -37 -67 83
Tax % 0% 0% 0% 0% 12% 4% -19%
-114 -130 -40 -33 -42 -69 98
EPS in Rs -6.02 8.61
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
21 128 39 172 1,445
93 132 199 254 978
Operating Profit -71 -4 -161 -82 467
OPM % -334% -3% -415% -48% 32%
1 -128 -526 -143 -94
Interest 16 46 48 89 166
Depreciation 34 53 66 76 274
Profit before tax -121 -231 -800 -391 -68
Tax % 0% -0% 0% 0% -73%
-121 -231 -800 -391 -18
EPS in Rs -1.57
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 124%
TTM: 740%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 33%
TTM: 130%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: -18%
Last Year: 3%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 2 3 4 4 11
Reserves 774 1,009 781 392 5,869
386 1,182 864 571 942
96 248 365 459 727
Total Liabilities 1,258 2,442 2,015 1,426 7,550
633 1,231 1,361 863 6,276
CWIP 431 490 334 188 60
Investments 0 0 4 20 16
195 722 314 356 1,199
Total Assets 1,258 2,442 2,015 1,426 7,550

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-118 -416 -163 -107 -68
-207 -692 -68 511 -201
381 1,162 118 -391 412
Net Cash Flow 56 54 -112 13 143

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 38 67 36 117 105
Inventory Days 87 615 258 133
Days Payable 762 420 163 147
Cash Conversion Cycle -637 67 232 212 91
Working Capital Days -1,085 271 -1,953 -259 59
ROCE % -3% -12% -12% 5%

Shareholding Pattern

Numbers in percentages

1 Recently
Dec 2024Mar 2025
37.76% 34.25%
17.44% 18.54%
12.56% 18.03%
32.24% 29.18%
No. of Shareholders 98,42582,712

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents